Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Calypso finds its rhythm

How rising interest in IL-15 helped six-year-old Calypso close its series A

Strong preclinical data and rising interest in IL-15 modulation enabled six-year-old Calypso Biotech B.V. to raise a €20 million ($22.6 million) series A round. The company hopes to start clinical trials next year of lead program CALY-002 to treat eosinophilic esophagitis (EoE).

Gilde Healthcare Partners and

Read the full 458 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers